Source link : https://www.newshealth.biz/health-news/ema-confirms-rejection-of-neurodegenerative-disease-drugs/
The European Medicines Agency (EMA) has upheld an earlier recommendation to deny marketing authorization for Masitinib AB Science (masitinib), an oral treatment for amyotrophic lateral sclerosis (ALS). In a meeting on October 17, the EMA’s Committee for Medicinal Products for Human Use (CHMP) reaffirmed its concerns about the reliability of the data supporting the drug. […]
Author : News Health
Publish date : 2024-10-18 16:11:43
Copyright for syndicated content belongs to the linked Source.